- Home
- REGN vs BUD Comparison
REGN vs BUD Comparison
Compare REGN & BUD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- BUD
- Stock Information
- Founded
- REGN 1988
- BUD 1366
- Country
- REGN United States
- BUD Belgium
- Employees
- REGN N/A
- BUD N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- BUD Beverages (Production/Distribution)
- Sector
- REGN Health Care
- BUD Consumer Staples
- Exchange
- REGN Nasdaq
- BUD Nasdaq
- Market Cap
- REGN 110.0B
- BUD 110.9B
- IPO Year
- REGN 1991
- BUD N/A
- Fundamental
- Price
- REGN $743.35
- BUD $55.20
- Analyst Decision
- REGN Buy
- BUD Buy
- Analyst Count
- REGN 24
- BUD 6
- Target Price
- REGN $1,110.63
- BUD $74.00
- AVG Volume (30 Days)
- REGN 837.3K
- BUD 2.1M
- Earning Date
- REGN 10-31-2024
- BUD 10-31-2024
- Dividend Yield
- REGN N/A
- BUD 1.59%
- EPS Growth
- REGN 15.31
- BUD 4.16
- EPS
- REGN 40.43
- BUD 3.19
- Revenue
- REGN $13,847,100,000.00
- BUD $59,400,000,000.00
- Revenue This Year
- REGN $10.13
- BUD $3.10
- Revenue Next Year
- REGN $4.00
- BUD $3.60
- P/E Ratio
- REGN $18.39
- BUD $16.96
- Revenue Growth
- REGN 5.72
- BUD N/A
- 52 Week Low
- REGN $736.01
- BUD $54.79
- 52 Week High
- REGN $1,211.20
- BUD $67.49
- Technical
- Relative Strength Index (RSI)
- REGN 13.08
- BUD 23.05
- Support Level
- REGN $813.53
- BUD $56.09
- Resistance Level
- REGN $834.42
- BUD $56.59
- Average True Range (ATR)
- REGN 19.56
- BUD 0.59
- MACD
- REGN -3.19
- BUD -0.17
- Stochastic Oscillator
- REGN 5.83
- BUD 7.64
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
About BUD Anheuser-Busch Inbev SA Sponsored ADR (Belgium)
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. The company's portfolio contains six of the top 10 beer brands by volume, according to Euromonitor, and we estimate it distributes 23 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and US-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 it acquired SABMiller.